• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, September 9, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

New device sheds light on mechanism, efficacy of arthritis treatment

Bioengineer by Bioengineer
June 4, 2019
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Credit: John Munson, Cornell University

ITHACA, N.Y. – The debate over how one of the most popular osteoarthritis treatments should be federally regulated could change, thanks to a Cornell University study and a new device that provides a better understanding of the science behind hyaluronic acid (HA) injections.

The medical community has been divided over exactly how HA injections provide pain relief to osteoarthritis patients. HA products, typically injected into the knee, replace naturally occurring HA that has been depleted, lubricating the joints and preventing bones from rubbing together.

These injections, used for arthritis treatment for more than 30 years, constitute a $1 billion market in the U.S. The products are currently classified by the U.S. Food and Drug Administration (FDA) as class III medical devices, meaning pain relief is achieved through mechanical actions – mainly the reduction in friction between the bones – as opposed to chemical actions.

But in December 2018, the FDA declared its intention to consider reclassifying HA products as drugs, citing scientific evidence that suggests HA achieves pain relief through chemical actions within the body. If reclassified, new HA products would face a much steeper challenge in reaching the market, affecting treatment options for the 30 million people in the U.S. who have osteoarthritis.

A new study led by Lawrence Bonassar, biomedical engineering and mechanical and aerospace engineering professor, provides new insight on HA’s mode of action. The researchers found the mechanical properties provided by HA’s viscosity, specifically its ability to effectively lubricate cartilage, correlate much more directly to clinical efficacy – i.e., pain relief – than previously thought.

“Researchers have typically used rheometry [the measurement of flow and deformation] to measure how HA reacts to applied forces and to predict its clinical performance, but our study shows it’s a poor predictor,” Bonassar said. “A lot of the disagreement over how HA works is rooted in the fact that, until now, there hasn’t been a better test of how mechanical properties predict performance.”

To test the viscosity of six different HA products, Bonassar’s team engineered a custom tribometer – a device used to measure coefficient of friction – that rubs cartilage back and forth on a glass plate and measures friction and how the products affect it.

“What we found was that each product’s lubricating properties directly correlated with the amount of pain relief reported in patient surveys. This is the first time anyone has been able to show such a clear correlation, and it suggests the debate over how HA works has been somewhat misinformed,” said Bonassar, suggesting that more research should be conducted before a decision is reached on HA treatment regulation.

Bonassar said the study also provides an effective framework from which new HA formulations can be tested, potentially leading to better products and treatment options for those with osteoarthritis.

###

The research, “Frictional Characterization of Injectable Hyaluronic Acids Is More Predictive of Clinical Outcomes Than Traditional Rheological or Viscoelastic Characterization,” was published in the journal PLoS One. Edward Bonnevie, currently a postdoctoral researcher at the University of Pennsylvania, was lead author. The study was co-authored by scientists from Fidia Farmaceutici S.p.A. of Padua, Italy, and supported by the National Science Foundation Graduate Research Fellowship program.

Cornell University has dedicated television and audio studios available for media interviews supporting full HD, ISDN and web-based platforms.

Media Contact
Lindsey Hadlock
[email protected]

Original Source

http://news.cornell.edu/stories/2019/05/study-could-inform-debate-over-arthritis-treatment-regulation

Related Journal Article

http://dx.doi.org/10.1371/journal.pone.0216702

Tags: Biomedical/Environmental/Chemical EngineeringMedicine/HealthOrthopedic MedicinePolicy/Ethics
Share13Tweet8Share2ShareShareShare2

Related Posts

blank

Tracing the Origins of Wnt Signaling Uncovers a Protein Superfamily Spanning the Tree of Life

September 9, 2025
blank

From Quantum Mechanics to Quantum Microbes: A Yale Scientist’s Revolutionary Journey of Discovery

September 9, 2025

Scientists Harness Breakthrough Tool to Advance Canine Cancer Treatment

September 9, 2025

Ferric Reductase Controls Iron Uptake in Blastocystis

September 9, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    151 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    56 shares
    Share 22 Tweet 14
  • Physicists Develop Visible Time Crystal for the First Time

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tracing the Origins of Wnt Signaling Uncovers a Protein Superfamily Spanning the Tree of Life

Revolutionary ‘On-Demand Blood’ Technology Promises to Transform Emergency Transfusions

Clinical Trial Indicates Pre-Surgery Immunotherapy as Promising Treatment for Rare Cancer

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.